Table 1 Patient characteristics of the immunotherapy and chemotherapy groups in the renal cancer cohort.
Demographic characteristics | Pembrolizumab | % | Nivolumab | % | All immunotherapy drugs | % | Chemotherapy | % |
|---|---|---|---|---|---|---|---|---|
Number of patients | Number of patients | Number of patients | Number of patients | |||||
Sex | ||||||||
Both sexes | 214 | 100.00 | 1003 | 100.00 | 1284 | 100.00 | 1425 | 100.00 |
Female | 71 | 33.18 | 249 | 24.83 | 336 | 26.17 | 523 | 36.70 |
Male | 143 | 66.82 | 754 | 75.17 | 948 | 73.83 | 902 | 63.30 |
Sex p-value | p = 0.3205 | p < 1e-04 | p < 1e-04 | Control group | ||||
Age | ||||||||
(0,40) | <5 | <2.34 | 29 | 2.89 | 34 | 2.65 | 195 | 13.68 |
(40,50) | 7 | 3.27 | 76 | 7.58 | 86 | 6.7 | 109 | 7.65 |
(50,60) | 29 | 13.55 | 256 | 25.52 | 295 | 22.98 | 301 | 21.12 |
(60,70) | 72 | 33.64 | 358 | 35.69 | 449 | 34.97 | 413 | 28.98 |
(70,80) | 64 | 29.91 | 217 | 21.64 | 304 | 23.68 | 291 | 20.42 |
(80,120) | 38 | 17.76 | 67 | 6.68 | 116 | 9.03 | 116 | 8.14 |
Age p-value | p < 1e-04 | p < 1e-04 | p < 1e-04 | Control group | ||||
Matched | 120 | 56.07 | 552 | 55.03 | 709 | 55.22 | Control group | |
